Latest news from the CGRP Forum

Artery studies confirm fremanezumab antagonism on CGRP vasodilatory effects

Fremanezumab competes with CGRP to a similar extent in human cerebral, middle meningeal and abdominal arteries, according to in vitro studies aimed at extending understanding of the vascular effects of CGRP blocking agents.

Read the full report here »

EMA reinforces actions to prevent valproate use for migraine prevention in pregnancy

Newly published guidance from the European Medicines Agency (EMA), in conjunction with the European Headache Federation, calls for more extensive restrictions on valproate prescribing to women with migraine, better public awareness, and a more effective education campaign to reduce the risk of in utero exposure.

Read the full report here »

Phase 2b patient-reported outcomes data published on galcanezumab

Significant functional improvements have been reported after 12 weeks treatment with galcanezumab in a post-hoc analysis of a Phase 2b study in patients with episodic migraine (NCT02163993).

Read the full report here »

Look out for multimorbidity in patients with chronic migraine and medication overuse headache

Recognising multimorbidity in patients with chronic migraine (CM) and medication overuse headache (MOH) is important for improving the management of these complex patients, conclude the authors of a study aimed at addressing the rate and impact of multimorbidity in this group.

Read the full report here »

Preschool abdominal migraine is best predictor of migraine at primary school age

Children under five who get abdominal migraine have a probability of getting migraine during their primary school years of over 50%, according to findings from a retrospective cohort study of 55,035 children born in 2006 with no diagnosis of migraine up to the age of five years. In contrast, other episodic syndromes experienced by under-fives are poor predictors of later migraine risk.

Read the full report here »

Climb every mountain – even if you get migraine

Climbers who get migraines or any type of headache at low altitude are only slightly more likely to get acute mountain sickness (AMS) at altitude than other climbers. A multivariate analysis using data from 1320 mountaineers staying overnight at the Capanna Margherita (4559 m) in Italy has shown that migraine or headache history is a minor predictor of AMS after accounting for major risk factors such as a history of AMS, rate of ascent and preacclimatisation.

Read the full report here »